Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “neutral” rating reiterated by DZ Bank AG in a note issued to investors on Monday.

QGEN has been the topic of a number of other reports. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, July 31st. Barclays PLC restated an “overweight” rating and issued a $37.00 price target (up from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, May 29th. BidaskClub downgraded shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, Independent Research GmbH upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Qiagen N.V. presently has a consensus rating of “Hold” and an average price target of $33.17.

Shares of Qiagen N.V. (NASDAQ QGEN) traded up 0.32% during mid-day trading on Monday, reaching $31.64. 56,739 shares of the company were exchanged. The firm’s 50-day moving average is $32.76 and its 200-day moving average is $31.36. The company has a market capitalization of $7.22 billion, a price-to-earnings ratio of 96.76 and a beta of 1.14. Qiagen N.V. has a 12 month low of $24.86 and a 12 month high of $35.26.

Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company had revenue of $349 million for the quarter, compared to the consensus estimate of $353.09 million. During the same period last year, the company posted $0.24 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities analysts forecast that Qiagen N.V. will post $1.22 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Qiagen N.V. (QGEN) Earns Neutral Rating from DZ Bank AG” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/28/qiagen-n-v-qgen-earns-neutral-rating-from-dz-bank-ag.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. M&T Bank Corp purchased a new position in Qiagen N.V. during the first quarter valued at about $230,000. Envestnet Asset Management Inc. purchased a new position in Qiagen N.V. during the first quarter valued at about $667,000. Parametric Portfolio Associates LLC raised its position in Qiagen N.V. by 4.1% in the first quarter. Parametric Portfolio Associates LLC now owns 651,832 shares of the company’s stock valued at $18,884,000 after buying an additional 25,582 shares during the last quarter. Karp Capital Management Corp purchased a new position in Qiagen N.V. during the first quarter valued at about $5,862,000. Finally, Bank of New York Mellon Corp raised its position in Qiagen N.V. by 13.7% in the first quarter. Bank of New York Mellon Corp now owns 1,222,959 shares of the company’s stock valued at $35,430,000 after buying an additional 147,752 shares during the last quarter. Hedge funds and other institutional investors own 63.01% of the company’s stock.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.